Lonza, a global partner to the pharmaceutical, biotech, and nutraceutical markets, announced today the addition of clinical bottling and labelling capabilities at its Small Molecules site in Bend, Oregon (US). Building upon the recent investment in the dedicated early-phase clinical manufacturing facility, the offering now includes new bottling equipment for filling tablets and powder-filled capsules. The additional equipment will further support customers in the early stages of development.
The new equipment can detect defects in tablets and capsules as well as clean, fill, cap and seal, and label bottles intended for use in early-phase clinical trials. This enables Lonza to speed up product delivery to clinical trial centres, which is crucial in its customers' journey toward clinical trials.
Matthew Ferguson, Senior Director, Product Development, Small Molecules, Lonza, commented: “Lonza’s Drug Product Formulation and Development Services, offered from our site in Bend (US), supports clinical and commercial development and manufacturing. The new bottling equipment for filling tablets and powder-filled capsules further enhances our ability to support customers looking to accelerate their candidate pathway through phase I and II clinical trials and beyond.”
Lonza’s facility in Bend serves as the company’s Center of Excellence for bioavailability enhancement and inhaled delivery. For more than 45 years, the Bend team has been at the forefront of addressing solubility challenges and modulating pharmacokinetics to meet target product profiles. The site currently supports more than 80 programmes.
Find out more by visiting Lonza at CHPI Milan on stand 6A2, excipients zone.
